Status:
COMPLETED
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
Lead Sponsor:
GE Healthcare
Collaborating Sponsors:
i3 Statprobe
Medpace, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-40 years
Phase:
PHASE3
Brief Summary
Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine h...
Eligibility Criteria
Inclusion
- The subject age is 18 to 40 years.
- The subject has no evidence of thinking or memory problems by medical history.
- The subject has a normal MRI scan.
- The subject's general health is adequate to comply with study procedures.
- The subject is willing and able to participate in all study procedures.
Exclusion
- The subject has received any medical ionizing radiation exposure in the last 12 months (except planar x-ray or head CT).
- The subject has a contraindication for (cannot undergo) MRI.
- The subject has a history of head injury with loss of consciousness.
- The subject has any significant medical, psychiatric or neurological condition that might be associated with brain pathology.
- The subject has a family history of Alzheimer's Disease (AD); more than 1 first-degree relative.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT01265394
Start Date
December 1 2010
End Date
April 1 2011
Last Update
July 2 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GE Healthcare
Princeton, New Jersey, United States, 08540